RxSight price target lowered to $11 from $22 at Needham

Needham lowered the firm’s price target on RxSight (RXST) to $11 from $22 and keeps a Buy rating on the shares after its Q2 results came in-line with its pre-announcement. RxSight has continued on its commercial pivot, which involves providing more support to its existing accounts in an attempt to drive utilization, though the firm is reducing its price target to reflect a lower multiple, the analyst tells investors in a research note.